These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27021495)

  • 41. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination.
    Kongsgaard M; Bassi MR; Rasmussen M; Skjødt K; Thybo S; Gabriel M; Hansen MB; Christensen JP; Thomsen AR; Buus S; Stryhn A
    Sci Rep; 2017 Apr; 7(1):662. PubMed ID: 28386132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.
    Barrett AD; Monath TP; Barban V; Niedrig M; Teuwen DE
    Vaccine; 2007 Apr; 25(15):2758-65. PubMed ID: 17368349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A clinician's perspective on yellow fever vaccine-associated neurotropic disease.
    Lecomte E; Laureys G; Verbeke F; Domingo Carrasco C; Van Esbroeck M; Huits R
    J Travel Med; 2020 Nov; 27(7):. PubMed ID: 32965473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Yellow fever vaccine for patients with HIV infection.
    Barte H; Horvath TH; Rutherford GW
    Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Yellow fever vaccination in non-immunocompetent patients].
    Bruyand M; Receveur MC; Pistone T; Verdière CH; Thiebaut R; Malvy D
    Med Mal Infect; 2008 Oct; 38(10):524-32. PubMed ID: 18715730
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eliminating yellow fever epidemics in Africa: Vaccine demand forecast and impact modelling.
    Jean K; Hamlet A; Benzler J; Cibrelus L; Gaythorpe KAM; Sall A; Ferguson NM; Garske T
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008304. PubMed ID: 32379756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.
    Pistone T; Verdière CH; Receveur MC; Ezzedine K; Lafon ME; Malvy D
    Curr HIV Res; 2010 Sep; 8(6):461-6. PubMed ID: 20636276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina.
    Ripoll C; Ponce A; Wilson MM; Sharif N; Vides JB; Armoni J; Teuwen DE
    Hum Vaccin; 2008; 4(2):121-6. PubMed ID: 18382132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long term persistence of yellow fever neutralising antibodies in elderly persons].
    Coulange Bodilis H; Benabdelmoumen G; Gergely A; Goujon C; Pelicot M; Poujol P; Consigny PH
    Bull Soc Pathol Exot; 2011 Oct; 104(4):260-5. PubMed ID: 21336654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication.
    Wieten RW; Jonker EF; Pieren DK; Hodiamont CJ; van Thiel PP; van Gorp EC; de Visser AW; Grobusch MP; Visser LG; Goorhuis A
    Vaccine; 2016 Mar; 34(10):1247-51. PubMed ID: 26845742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The elderly, the young and the pregnant traveler -- A retrospective data analysis from a large Swiss Travel Center with a special focus on malaria prophylaxis and yellow fever vaccination.
    Jaeger VK; Tschudi N; Rüegg R; Hatz C; Bühler S
    Travel Med Infect Dis; 2015; 13(6):475-84. PubMed ID: 26526774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccinations and malaria prophylaxis for long-term travellers travelling from Greece: a prospective, questionnaire-based analysis.
    Pavli A; Smeti P; Spilioti A; Silvestros C; Katerelos P; Maltezou HC
    Travel Med Infect Dis; 2014; 12(6 Pt B):764-70. PubMed ID: 24957561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Yellow fever vaccine: an effective vaccine for travelers.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of yellow fever vaccine in Indian travellers: A prospective observational study.
    Tiwari P; Ahlawat R; Gupta G
    Indian J Med Res; 2016 Nov; 144(5):778-780. PubMed ID: 28361832
    [No Abstract]   [Full Text] [Related]  

  • 56. Yellow fever vaccine safety: a reality or a myth?
    Arya SC
    Vaccine; 2002 Nov; 20(31-32):3627-8. PubMed ID: 12399186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal myelitis associated with yellow fever vaccination.
    Chaves M; Riccio P; Patrucco L; Rojas JI; Cristiano E
    J Neurovirol; 2009 Jul; 15(4):348-50. PubMed ID: 19579072
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prescription of Yellow Fever Vaccine: The Experience of the International Vaccination Centre of the Loures-Odivelas Health Centre Group].
    Martinho C; Lopes D; Bastos L; Esteves H
    Acta Med Port; 2018 Dec; 31(12):724-729. PubMed ID: 30684369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of fatal adverse events associated with 17DD yellow fever vaccine.
    Struchiner CJ; Luz PM; Dourado I; Sato HK; Aguiar SG; Ribeiro JG; Soares RC; Codeço CT
    Epidemiol Infect; 2004 Oct; 132(5):939-46. PubMed ID: 15473158
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality improvement in travel medicine: a programme for yellow fever vaccination centres in England, Wales and Northern Ireland.
    Boddington NL; Simons H; Launders N; Hill DR
    Qual Prim Care; 2011; 19(6):391-8. PubMed ID: 22340901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.